StockNews.com Begins Coverage on LadRx (NASDAQ:CYTR)

Investment analysts at StockNews.com assumed coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Tuesday. The firm set a “hold” rating on the stock.

LadRx Stock Performance

NASDAQ:CYTR opened at $0.09 on Tuesday. LadRx has a fifty-two week low of $0.05 and a fifty-two week high of $0.86. The firm’s 50-day simple moving average is $0.10.

LadRx Company Profile

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.